The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen THOUSAND OAKS, Calif., Feb. 24, 2026 /PRNewswir ...

th PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 46 Annual Health Care Conference on Monday, March 2, 2026. The company will take part in a fireside chat beginning at 9:50 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives T ...

Core Insights - The article discusses the 15 best S&P 500 dividend stocks to consider for investment in 2026, emphasizing the stability that dividend stocks can provide during market downturns [1] Dividend and Buyback Strategy - Dan Lefkovitz from Morningstar Indexes suggests that combining dividend-paying stocks with companies that actively buy back shares can yield better returns compared to a high-dividend-only strategy [2] - An index that includes both dividends and buybacks has outperformed a high-dividend-only index over the past three years, although it still lags behind the overall US market [2] Cash Return to Shareholders - The article highlights the difference in how companies return cash to shareholders, noting that dividends are a long-term commitment while buybacks are more flexible and often increase when management perceives the stock as undervalued [3] - Large technology companies have been leading in buyback activities, while dividend payments are primarily concentrated in sectors like financials, utilities, energy, and consumer staples [3] International Dividend Yields - Income-focused investors are encouraged to look beyond the US, as domestic dividend yields have decreased to approximately 1.1%, while some European regions offer yields above 3% [4] - Caution is advised against chasing high yields, as unusually high payouts may indicate underlying business stress and potential future dividend cuts [4] Methodology for Stock Selection - The selection process for the 15 best dividend stocks involved screening S&P 500 companies with a market cap of at least $10 billion, focusing on those with stable dividends and yields around 2% as of January 21 [6] - The final list was based on popularity among hedge funds, utilizing data from Insider Monkey's Q3 2025 database [6][7] Company-Specific Insights - **Verizon Communications Inc. (NYSE:VZ)**: - Holds a dividend yield of 7.06% as of January 21, with 60 hedge fund holders [8] - Bernstein has cut its price target for Verizon to $44, citing increased competition in the telecom industry [8] - Verizon's $20 billion acquisition of Frontier Communications was approved, with commitments to expand fiber internet and wireless coverage in California [9] - **Amgen Inc. (NASDAQ:AMGN)**: - Has a dividend yield of 3.05% as of January 21, with 62 hedge fund holders [11] - Bernstein downgraded Amgen to Market Perform, indicating 2026 may be a waiting year for its product MariTide [11] - Amgen announced the acquisition of Dark Blue Therapeutics for up to $840 million, enhancing its oncology pipeline [12][13]

Core Insights - Johnson & Johnson has demonstrated strong financial performance, achieving $94.2 billion in sales for the year, a 6% increase from the previous year, and $26.2 billion in adjusted net earnings, reflecting an over 8% increase [3] - The company maintains a robust dividend yield of 2.4%, significantly higher than the S&P 500's yield of 1.2%, and has a history of increasing dividends for 63 consecutive years, qualifying it as a Dividend King [2][4] Financial Performance - Johnson & Johnson reported $19.7 billion in free cash flow, which comfortably covered its $12.4 billion in dividend payments, allowing the company to maintain a healthy balance sheet [4] - The company ended the year with $20 billion in cash and marketable securities against $48 billion in debt, resulting in a net debt of approximately $28 billion, which is manageable given its market capitalization of over $520 billion [4] Future Growth Prospects - The company anticipates sales growth of over 6% in 2026, projecting to exceed $100 billion in sales, alongside adjusted earnings-per-share growth of 6% to 8% [6] - Johnson & Johnson's significant investment in research and development, totaling $14.7 billion last year, supports its ability to deliver innovative medical technologies and medicines [7] - Recent acquisitions, including the $14.6 billion purchase of Intra-Cellular Therapies and the $3.1 billion acquisition of Halda Therapies, are expected to enhance growth and expand its healthcare solutions [7] Dividend Stability - The company's strong cash flow and solid balance sheet indicate that it can continue to provide a steadily rising dividend payout in the future, reinforcing its status as a reliable dividend stock [8]

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has received upgrades in its credit ratings from S&P Global Ratings and Moody's, indicating significant progress towards achieving investment-grade status [1][7]. Financial Performance - S&P upgraded Teva's long-term issuer credit rating to 'BB+' from 'BB', with a stable outlook, while Moody's affirmed a B1a rating and revised the outlook to positive from stable [1][7]. - Teva's adjusted leverage declined to 4.4x as of September 30, 2025, with expectations to fall below 4.25x in the coming quarters, meeting the threshold for a higher rating [2]. - Moody's noted expectations for leverage to decline toward 3.5x within 12–18 months, supporting the positive outlook [3]. Business Strategy - Teva's financial discipline and strong business performance have been highlighted, with a return to revenue growth after five years of declines, driven by robust performance in branded medicines and stabilization in generics [2]. - The company is focusing on its "Pivot to Growth" strategy, emphasizing cash flow management and capital allocation to support deleveraging and sustainable growth [4]. Product Development - Moody's cited strong momentum in Teva's branded franchises and upcoming product launches across both branded and biosimilar portfolios, which are expected to offset challenges in the generics segment [3].

Core Insights - Regeneron Pharmaceuticals is a leading biotechnology company focused on innovative treatments for serious diseases, competing with major players like Amgen and Biogen [1][5] - Truist Financial has set a price target of $798 for Regeneron, indicating a potential price increase of 4.11% from its current price of $766.50 [1][5] Stock Performance - Regeneron's stock is currently priced at $768.79, reflecting a 1.71% increase, or $12.89, from its previous value [2] - The stock has fluctuated between $757 and $773.13 today, indicating active investor interest [2] - Over the past year, the stock has reached a high of $800.99 and a low of $476.49, showcasing its growth potential and challenges faced [4] Market Capitalization and Trading Activity - Regeneron's market capitalization is approximately $79.4 billion, highlighting its significant presence in the biotech industry [3][5] - The trading volume today is 156,611 shares on the NASDAQ exchange, suggesting that investors are closely monitoring Regeneron's performance amid market volatility [3]

Core Insights - AbbVie Inc. is a research-based biopharmaceutical company with a market cap of $385.2 billion, focusing on innovative medicines across various therapeutic areas [1] Performance Overview - Over the past 52 weeks, AbbVie shares have increased by 6.6%, underperforming the S&P 500 Index, which rose by 17.7%. However, year-to-date, AbbVie stock is up 22.1%, outperforming the S&P 500's 16.3% increase [2] - AbbVie has also outperformed the iShares U.S. Healthcare ETF, which saw a 2.9% decline over the past 52 weeks and a 4.4% increase year-to-date [3] Financial Results - AbbVie reported Q3 earnings on October 31, with a 9.1% year-over-year revenue growth to $15.8 billion, exceeding consensus estimates by 1.2%. Adjusted EPS fell 38% year-over-year to $1.86 but surpassed analyst expectations of $1.77 [4] - The company raised its fiscal 2025 adjusted EPS guidance to a range of $10.61 to $10.65, despite a 4.5% drop in shares following the earnings report, attributed to a $1.50-per-share impact from acquired R&D and milestone expenses [4] Analyst Expectations - For the current fiscal year ending in December, analysts project AbbVie's EPS to grow by 4.6% year-over-year to $10.58. AbbVie has consistently surpassed consensus estimates in the last four quarters [5] - The consensus rating among 28 analysts is a "Moderate Buy," with 15 "Strong Buy," 2 "Moderate Buy," and 11 "Hold" ratings [5] Analyst Ratings and Price Target - The analyst configuration has slightly shifted, with 16 analysts now suggesting a "Strong Buy" rating. On November 3, JPMorgan Chase & Co. maintained an "Overweight" rating on AbbVie and raised its price target to $260, indicating a potential upside of 22.2% from current levels [6]

Core Viewpoint - Bristol-Myers Squibb Co. is expected to report a decline in Q3 2025 earnings, with analysts projecting an EPS of $1.67 and quarterly revenue of $11.76 billion, indicating a decrease from the previous year [2] Financial Performance - The company reported Q2 2025 earnings with an adjusted EPS of $1.46, which was below the consensus estimate of $1.58, while revenues of $12.30 billion exceeded the consensus of $11.31 billion [3] - Bristol-Myers Squibb's dividend yield stands at 5.37%, with a total dividend payout of $2.48 per share over the last 12 months [2] Future Guidance - The company has raised its full-year 2025 revenue guidance from approximately $45.8 billion to $46.8 billion to a new range of $46.5 billion to $47.5 billion [4] - CEO Christopher Boerner emphasized the focus on advancing transformational medicines and optimizing the company's cost structure to support long-term growth [4]

Group 1 - Amgen will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 9:20 a.m. PT, featuring executives Peter Griffith and Jay Bradner [1] - The webcast of the presentation will be available on Amgen's website and archived for at least 90 days [2] - Amgen is recognized for its innovative medicines and has a strong pipeline targeting various diseases, including cancer and heart disease [3] Group 2 - In 2024, Amgen received accolades such as being named one of the "World's Most Innovative Companies" and "America's Best Large Employers" [4] - Amgen is part of the Dow Jones Industrial Average and the Nasdaq-100 Index, highlighting its market significance [4]

Core Viewpoint - Roche announced a commitment to invest USD 50 billion in the United States over the next five years, aimed at enhancing its manufacturing and R&D capabilities, which is expected to create over 12,000 new jobs [1][2][6]. Company Investment and Expansion - The investment will expand Roche's existing footprint of more than 25,000 employees across 24 sites in eight US states [2][6]. - New facilities will include state-of-the-art R&D sites and expanded manufacturing capabilities in Indiana, Pennsylvania, Massachusetts, and California, with an additional site to be announced [6][7]. Job Creation - The investment is projected to create more than 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities [1][6]. Manufacturing and R&D Focus - Roche will enhance its manufacturing and distribution capabilities for innovative medicines and diagnostics in states such as Kentucky, Indiana, New Jersey, Oregon, and California [7]. - A new gene therapy manufacturing facility will be established in Pennsylvania, along with a 900,000 square foot manufacturing center for next-generation weight loss medicines [7]. Commitment to Innovation - The investment is positioned as a foundation for Roche's next era of innovation and growth, benefiting patients in the US and globally [2][6]. - Roche's CEO emphasized the company's long-standing commitment to research, development, and manufacturing in the US, highlighting its 110-year legacy in the country [2].